

## HEPATOLOGY JULY ANSWERS

QUESTIONS	ANSWERS
<p>1. To predict long-term treatment outcomes, when should we measure HBV DNA levels after the initiation of lamivudine therapy?</p> <ul style="list-style-type: none"><li>a. 4 weeks and 24 weeks</li><li>b. 3 weeks and 23 weeks</li><li>c. 2 weeks and 22 weeks</li><li>d. 1 week and 21 weeks</li></ul>	a
<p>2. Which of the following baseline HBeAg-positive patient characteristics indicate good long-term outcomes when treated with lamivudine?</p> <ul style="list-style-type: none"><li>a. Good treatment response at week 24</li><li>b. HBV DNA &lt;9 log copies/mL</li><li>c. ALT <math>\geq 2 \times</math> ULN</li><li>d. All of the above</li></ul>	d
<p>3. Antiviral therapy should be continued, even after HBeAg seroconversion because continuing therapy can minimize the chance of ALT flares.</p> <ul style="list-style-type: none"><li>a. True</li><li>b. False</li></ul>	a
<p>4. Patients achieving HBsAg seroclearance do not require continued monitoring of the disease.</p> <ul style="list-style-type: none"><li>a. True</li><li>b. False</li></ul>	b